Richard Scott Struthers - 15 Apr 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
15 Apr 2024
Transactions value $
$38,200
Form type
4
Filing time
17 Apr 2024, 16:30:22 UTC
Previous filing
08 Apr 2024
Next filing
22 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $38,200 +20,000 +8.41% $1.91* 257,835 15 Apr 2024 Direct
holding CRNX Common Stock 570,805 15 Apr 2024 By Family Trust 1
holding CRNX Common Stock 110,000 15 Apr 2024 By Family Trust 2
holding CRNX Common Stock 110,000 15 Apr 2024 By Family Trust 3
holding CRNX Common Stock 110,000 15 Apr 2024 By Family Trust 4
holding CRNX Common Stock 1,000 15 Apr 2024 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Options Exercise $0 -20,000 -19.75% $0 81,270 15 Apr 2024 Common Stock 20,000 $1.91 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.